ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients

ITM Isotope Technologies reported updated preliminary Phase 1 results for ITM-31 (177Lu-6A10-Fab) in newly diagnosed glioblastoma, with a manageable safety profile and all 10 enrolled patients alive since enrollment began in January 2024. The investigator-initiated, single-arm dose-escalation trial is complete for enrollment, and six-month follow-up is expected by end-2026. ITM-31 delivers targeted Lutetium-177 radiation into the post-surgical resection cavity to target CA XII–expressing residual tumor cells while minimizing systemic toxicity.

Analysis

This is more a platform-validation datapoint than a fundable oncology asset readthrough. In glioblastoma, the market typically overpays for any signal that suggests bypassing the blood–brain barrier, but phase 1 safety in a ten-patient, single-arm study does not yet prove commercial efficacy or even class relevance. The biggest near-term beneficiary is likely ITM’s partnering optionality: a tolerable intracavitary delivery approach can be used to reprice the company’s broader radiopharma capabilities, even if the asset itself never becomes a blockbuster.

The second-order implication is competitive, not clinical. If the maintenance/local-control thesis holds, it could pull future development dollars toward post-resection, loco-regional oncology programs rather than systemic CNS agents, pressuring companies betting on peripheral delivery or immune-only approaches in GBM. That said, the bar for glioblastoma capital is brutally high; investors will demand a survival delta that is durable versus standard-of-care recurrence, and anything short of a clear PFS/OS signal will likely fade into the background by the time six-month follow-up completes.

Timing matters: any stock reaction should be treated as a days-to-weeks sentiment move, while the real catalyst window is 1-3 months around additional dose/escalation disclosures and then 6-18 months for follow-up maturation. The contrarian risk is that the current optimism is front-running data that are mostly de-risking toxicity rather than proving biology; if later cohorts show feasibility but no separation in progression outcomes, the story can quickly revert to optionality with limited intrinsic value. Watch for financing needs and any partnering announcement cadence—those will tell you whether management is using this as a genuine asset monetization path or just a platform marketing update.

Key Decisions for Investors

• No immediate directional trade on the headline alone; treat this as a watch item until the next efficacy cut and six-month follow-up, because phase 1 safety is insufficient to underwrite valuation.
• If ITM is publicly listed and the stock trades up on the release, consider fading strength into a 1-3 day overreaction rather than chasing; the falsifier would be an independent PFS/OS signal at follow-up, not the current tolerability data.
• For investors already long the radiopharma complex, use this as a catalyst to stay overweight platform names with near-term clinical readouts, but avoid extrapolating to CNS therapeutics until more patients and durability data emerge.
• Set an alert for the end-of-2026 follow-up and any interim dose-escalation update; a meaningful signal would be a clean safety profile plus evidence of delayed recurrence versus historical glioblastoma benchmarks.
• If seeking a relative-value expression, prefer a basket/ETF view over a single-name bet: long validated radioligand leaders with commercial cash flow, short or underweight speculative pre-proof CNS oncology developers that are likely to see multiple compression if this readout remains inconclusive.